GLP-1 Initiation Did Not Improve Insulin Discontinuation Rates Among Veterans with Type 2 Diabetes

Source Summary

A target trial emulation found that adding glucagon-like peptide-1 receptor agonists (GLP-1RAs) to basal insulin therapy for type 2 diabetes did not increase the likelihood of stopping insulin therapy compared with adding sodium-glucose cotransporter-2 inhibitor (SGLT-2i) or dipeptidyl peptidase-4 inhibitor (DPP-4i) therapy.